Sponsored Links
| Teva Announces Successful Results Of Phase III Study Of Its Long-Acting G-CSF Product (Lipegfilgrastim) In Breast Cancer Patients |
 |
 |
 |
| Medical News - Breast Cancer | |||
|
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that lipegfilgrastim (INN; internal code - XM22) achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™)... Read more: Breast Cancer News From Medical News Today
|